LGR4 Modulates Breast Cancer Initiation, Metastasis, and Cancer Stem Cells
Zhiying Yue,Zengjin Yuan,Li Zeng,Ying Wang,Li Lai,Jing Li,Peng Sun,Xiwen Xue,Junyi Qi,Zhengfeng Yang,Yansen Zheng,Yuanzhang Fang,Dali Li,Stefan Siwko,Yi Li,Jian Luo,Mingyao Liu
DOI: https://doi.org/10.1096/fj.201700897r
2017-01-01
Abstract:The fourth member of the leucine‐rich repeat‐containing GPCR family (LGR4, frequently referred to as GPR48) and its cognate ligands, R‐spondins (RSPOs) play crucial roles in the development of multiple organs as well as the survival of adult stem cells by activation of canonical Wnt signaling. Wnt/β‐catenin signaling acts to regulate breast cancer; however, the molecular mechanisms determining its spatiotemporal regulation are largely unknown. In this study, we identified LGR4 as a master controller of Wnt/β‐catenin signaling‐mediated breast cancer tumorigenesis, metastasis, and cancer stem cell (CSC) maintenance. LGR4 expression in breast tumors correlated with poor prognosis. Either Lgr4 haploinsufficiency or mammary‐specific deletion inhibited mouse mammary tumor virus (MMTV)‐PyMT‐ and MMTV‐Wnt1‐driven mammary tumorigenesis and metastasis. Moreover, LGR4 down‐regulation decreased in vitro migration and in vivo xenograft tumor growth and lung metastasis. Furthermore, Lgr4 deletion in MMTV‐Wnt1 tumor cells or knockdown in human breast cancer cells decreased the number of functional CSCs by ~90%. Canonical Wnt signaling was impaired in LGR4‐deficient breast cancer cells, and LGR4 knockdown resulted in increased E‐cadherin and decreased expression of N‐cadherin and snail transcription factor ‐2 (SNAI2) (also called SLUG), implicating LGR4 in regulation of epithelial–mesenchymal transition. Our findings support a crucial role of the Wnt signaling component LGR4 in breast cancer initiation, metastasis, and breast CSCs.—Yue, Z., Yuan, Z., Zeng, L., Wang, Y., Lai, L., Li, J., Sun, P., Xue, X., Qi, J., Yang, Z., Zheng, Y., Fang, Y., Li, D., Siwko, S., Li, Y., Luo, J., Liu, M. LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells. FASEB J. 32, 2422–2437 (2018). www.fasebj.org